When regulatory shifts from a final step to a driver of development
In the development of bioinputs, regulatory should not be viewed as a bureaucratic step to be addressed only at the end of the process. Instead, it is a strategic decision that can directly influence the product’s technical feasibility, time-to-market, development costs, and its sustainability throughout the entire lifecycle.
It is still common for regulatory to be treated in a reactive way, limited to the submission phase for registration. However, in practice, the key factors that determine the regulatory success of a bioinput are defined much earlier—during the initial stages of research and development. Among these factors are:
- the definition of the active ingredient;
- the selection and standardization of the production process;
- the choice of components, co-formulants, and additives;
- the definition of the formulation type;
- stability studies and shelf-life determination;
- demonstration and characterization of the mode or mechanism of action;
- technical specifications and quality control criteria.
These decisions have a direct impact on the product’s regulatory classification, the level of technical requirements, and the time needed to obtain registration—especially in a market like Brazil, where the regulatory framework for bioinputs is still evolving.
Regulatory classification
The Brazilian Bioinputs Law (Law No. 15.070/24), enacted in December 2024, introduced a broader and more comprehensive legal definition of bioinputs.
However, the decree that will regulate this law is still under development by the government. As a result, the current regulatory framework remains in place, taking into account the different possible classifications for bioinputs. Depending on label claims, a product may fall under either crop protection (pesticide) legislation or fertilizer regulations.
The correct regulatory classification is critical, as it determines investment levels, technical requirements, necessary laboratory studies, field efficacy trials, regulatory authorities involved, timelines, and other specific aspects. This reinforces the importance of incorporating regulatory strategy from the earliest stages of bioinput development.
The Brazilian Bioinputs Law (Law No. 15.070/24), enacted in December 2024, introduced a broader and more comprehensive legal definition of bioinputs.
However, the decree that will regulate this law is still under development by the government. As a result, the current regulatory framework remains in place, taking into account the different possible classifications for bioinputs. Depending on label claims, a product may fall under either crop protection (pesticide) legislation or fertilizer regulations.
The correct regulatory classification is critical, as it determines investment levels, technical requirements, necessary laboratory studies, field efficacy trials, regulatory authorities involved, timelines, and other specific aspects. This reinforces the importance of incorporating regulatory strategy from the earliest stages of bioinput development.
Impacts of late regulatory decisions
When regulatory considerations are not structured from the beginning of a project, the consequences are often significant and recurring, such as:
- generation of data and studies that cannot be fully used in the registration dossier;
- the need to supplement or repeat studies;
- technical rework in R&D and formulation;
- significant delays in bringing the product to market.
In many cases, high-potential projects are paused or discontinued because they require returning to earlier development stages to meet regulatory requirements—often at a point where budget or strategic timing is no longer viable.
Additionally, aspects that are often considered secondary can become critical, such as:
- validation of analytical methodologies to identify active ingredients or markers;
- structure and traceability of quality control systems;
- standardization of production processes at industrial scale;
- batch-to-batch consistency.
These elements are essential to ensure a product that is reproducible, competitive, and scientifically defensible from a regulatory standpoint.
The regulatory timeline as a strategic tool
Another key aspect is regulatory timeline planning. Aligning company and product regulatory strategies with technical data generation enables:
- optimization of overall development time;
- better use of seasonal windows for efficacy trials;
- construction of a more robust regulatory dossier from the outset;
- reduction of the risk of additional technical requirements;
- increased predictability and faster approval processes.
More than developing a technically effective bioinput, it is essential to ensure that it is viable, registrable, and sustainable within an increasingly technical, demanding, and competitive regulatory environment in Brazil.
In this context, regulatory moves beyond an operational role and becomes a truly strategic driver in the development of bioinputs.
Vigna Brasil’s role
Vigna Brasil is one of the pioneering regulatory consulting firms in the bioinputs sector, with active participation in structuring regulatory strategies for companies and products that are now well-established in the Brazilian market.
In addition to supporting established companies, Vigna Brasil maintains a strong commitment to the innovation ecosystem, working with startups and emerging technologies, and contributing to the strengthening and expansion of the bioinputs sector in Brazil and globally.
Get in touch with us and discover how to integrate regulatory strategy into bioinput R&D from the very beginning—ensuring greater predictability, efficiency, and confidence throughout the registration process.